Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD
2021-002251-11Phase 2Completed
- Sponsor
- Transposon Therapeutics, Inc.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of censavudine in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), sponsored by Transposon Therapeutics, Inc. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Aug 2021; status: completed.
02
Drugs
censavudine
03
Conditions
amyotrophic lateral sclerosis (ALS)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on 2021-002251-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002251-11.